VIDEO
HIGHLIGHT
Log InSign up
Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent [AMA 45 sneak peek]
SummaryTranscriptChat

Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent [AMA 45 sneak peek]

Introduction

In this section, the hosts introduce themselves and discuss the upcoming topics of discussion.

Book Launch

  • The hosts discuss their upcoming book launch, which is two weeks away from the recording of this podcast.
  • They express their surprise at how far they have come with the book and how it has managed to survive despite setbacks.

Topics of Discussion

  • The hosts introduce the two main topics for discussion: GLP-1 agonists and metformin data.
  • They acknowledge that these topics have been covered before but there are new insights to share.

GLP-1 Agonists

In this section, the hosts discuss GLP-1 agonists, what they are, why they are important, and their experiences with them.

What Are GLP-1 Agonists?

  • The hosts explain that GLP-1 or glucagon-like peptide one is a hormone in the body that regulates blood sugar levels.
  • They describe how GLP-1 agonists work by mimicking this hormone to help regulate blood sugar levels in people with type 2 diabetes.

Importance of GLP-1 Agonists

  • The hosts discuss how semi-glutide is currently one of the most talked-about drugs due to its effectiveness in treating type 2 diabetes and obesity.
  • They mention other drugs like branded Ozempic and Terzapatide that fall under this category as well.

Experiences with GLP-1 Agonists

  • One host shares his experience using semi-glutide on patients in his clinic.
  • They discuss how their understanding of GLP-1 agonists has evolved over the years and how they have become more confident in recommending them to patients.

Metformin Data

In this section, the hosts discuss metformin data and its potential as a longevity agent.

Metformin for Longevity

  • The hosts discuss how metformin is commonly used to treat type 2 diabetes but there is growing interest in its potential as a longevity agent.
  • They explain that studies have shown that metformin can improve healthspan and lifespan in animals and humans.

Thoughts on Metformin

  • The hosts share their thoughts on using metformin as a longevity agent, including concerns about side effects and dosages.
  • They also mention ongoing studies that are looking at the effectiveness of metformin for anti-aging purposes.

Conclusion

In this podcast episode, the hosts discussed GLP-1 agonists and metformin data. They provided an overview of what these drugs are, why they are important, and shared their experiences with them. Additionally, they discussed the potential of using metformin as a longevity agent and shared their thoughts on its use.

Introduction to Type 2 Diabetes and Glucose Regulation

This section introduces type 2 diabetes as a disorder of carbohydrate metabolism, characterized by insulin resistance and high blood glucose levels. The figure presented shows the strategic plan for using drugs that stimulate insulin release or inhibit glucagon release to lower blood glucose levels.

Type 2 Diabetes and Glucose Regulation

  • Type 2 diabetes is characterized by extreme insulin resistance in muscle cells, leading to high blood glucose levels.
  • Drugs that stimulate insulin release or inhibit glucagon release can help lower blood glucose levels.
  • GLP1 and GIP are two hormones that act through both arms of this strategic plan, stimulating insulin release and inhibiting glucagon release.

GLP-1 Agonists and Weight Loss

This section discusses the observation that people taking GLP-1 agonists not only improve glycemic control but also lose weight. The exact mechanism behind this effect is not clear, but it is believed to be a central effect on appetite reduction.

GLP-1 Agonists and Weight Loss

  • People taking GLP-1 agonists experience reduced appetite, eat less, and lose weight.
  • The exact mechanism behind this effect is not clear, but it is believed to be a central effect on appetite reduction.

Metformin and SGLT2 Inhibitors for Type 2 Diabetes Treatment

This section discusses different drugs used for treating type 2 diabetes. Metformin primarily reduces glucose production while SGLT2 inhibitors impair glucose reabsorption in the kidneys.

Metformin and SGLT2 Inhibitors for Type 2 Diabetes Treatment

  • Metformin primarily reduces glucose production, while SGLT2 inhibitors impair glucose reabsorption in the kidneys.
  • SGLT2 inhibitors have been shown to have benefits on longevity.

Introduction

In this section, the speaker introduces the topic of discussion which is GLP-1 agonists and their use in treating diabetes and obesity.

Background Information

  • GLP-1 agonists are used to treat diabetes and obesity.
  • There are two types of drugs used in treating diabetes: sulfona ureas and incritin therapies.

Use of GLP-1 Agonists for Weight Loss

In this section, the speaker discusses how people who do not have type 2 diabetes but want to lose weight are reaching out to him about using GLP-1 agonists.

Need for Weight Loss

  • Some people need to lose weight due to being overweight or having a high body fat percentage.
  • Others want to lose weight for cosmetic reasons such as looking good on vacation.

Definition of Gero Protective Drugs

In this section, the speaker defines gero protective drugs and explains how they differ from other drugs that improve longevity.

Definition of Gero Protective Drugs

  • Gero protective drugs act broadly across various different hallmarks of aging.
  • They improve lifespan and health span beyond just guacamole one disease at a time.

Comparison between Semaglutide and Zepatide

In this section, the speaker compares semaglutide and zepatide, two types of GLP-1 agonists used in treating obesity.

Semaglutide vs Zepatide

  • Semaglutide is a pure GLP-1 agonist while zepatide is a dual agonist that targets both GLP-1 receptors and glucagon receptors.
  • Semaglutide has a comparable affinity to pure GLP-1 while zepatide has a higher affinity to both receptors.
  • Semaglutide is available in three doses while zepatide is still in clinical trials.

[CUTOFF_LIMIT]

Video description

Watch the full episode and view show notes here: http://bit.ly/3Tap47T Become a member to receive exclusive content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ In this “Ask Me Anything” (AMA) episode, Peter focuses the discussion on two topics getting a lot of attention recently. He first dives deep into GLP-1 agonists, most notably semaglutide and tirzepatide, which originally came to market as diabetes drugs but are now being studied and prescribed for weight loss. He walks through the data and compares the effectiveness of the two drugs, the side effects, and perhaps more importantly, his reservations around wide use of these drugs and who he would consider to be a candidate for them. Next, Peter discusses how metformin, another drug originally brought to market for diabetes management, gained popularity as a potential longevity drug even for non-diabetics. Peter gives his take on this possibility and reviews data from a more recent study investigating the question of whether metformin should be used for general “geroprotection.” In this sneak peek, we discuss: 00:00 - Intro 00:08 - The hype around semaglutide, tirzepatide, and other GLP-1 agonists for weight loss 04:09 - Overview of GLP-1 agonists and why these drugs are getting so much attention 12:20 - Defining the term “geroprotective” 14:08 - Semaglutide: background, brand names, indications, and more 19:10 - Tirzepatide: background, brand names, indications, and more In the full episode, we also discuss: -How semaglutide and tirzepatide compare in their efficacy in terms of weight loss and other metabolic health metrics; -Data showing sustained weight loss and improved metabolic metrics with after more than a year of using semaglutide and tirzepatide; -What happens to body weight when a patient discontinues the medication?; -Noteworthy side effects of GLP-1 agonists and similar classes of drugs; -Increased resting heart rate and other concerning trends in patients using GLP-1 agonists; -Changes in body composition (body fat and lean muscle) in patients on GLP-1 agonists; -Possible reasons for the loss of lean muscle mass and tips for protecting lean mass; -GLP-1 agonists and thyroid cancer; -Who might be a candidate for GLP-1 agonists?; -The large financial cost of this class of drugs; -Metformin as a geroprotective drug: origin of the idea that metformin could be a longevity agent even for non-diabetic patients; -A 2022 study on metformin sheds more light on the question of whether metformin should be used for “geroprotection” in non-diabetics; -Peter’s current approach with metformin for his patients; and -More. -------- About: The Peter Attia Drive is a weekly, ultra-deep-dive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 45 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more. Peter is a physician focusing on the applied science of longevity. His practice deals extensively with nutritional interventions, exercise physiology, sleep physiology, emotional and mental health, and pharmacology to increase lifespan (delay the onset of chronic disease), while simultaneously improving healthspan (quality of life). Learn more: https://peterattiamd.com Connect with Peter on: Facebook: http://bit.ly/PeterAttiaMDFB Twitter: http://bit.ly/PeterAttiaMDTW Instagram: http://bit.ly/PeterAttiaMDIG Subscribe to The Drive: Apple Podcast: http://bit.ly/TheDriveApplePodcasts Overcast: http://bit.ly/TheDriveOvercast Spotify: http://bit.ly/TheDriveSpotify Google Podcasts: http://bit.ly/TheDriveGoogle Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. I take conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit my website where I keep an up-to-date and active list of such companies.

Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent [AMA 45 sneak peek] | YouTube Video Summary | Video Highlight